As biosims win nods in Europe and India, debate over naming rights heats up

Alok Saboo

What's in a name? In the pharmaceutical world, the answer to this question is no simple matter. Drugmakers, biotechs and their generic rivals are squabbling the names that will be assigned to biosimilars, in a battle for a marketing edge.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS